The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of York Charles N Ii since 2017.
This trader's CIK number is 1655962.
At the time of last reporting, York Charles N Ii was the COO and CFO of Day One Biopharmaceuticals, Inc.. (stock ticker symbol DAWN).
Also see all insider trading activities at Day One Biopharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | AGLE | 25,959 | $116,216 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | DAWN | 0 | $0 | 12,758 | $106,859 | 50,625 | $0 |
| 2024 | DAWN | 0 | $0 | 71,037 | $1,236,085 | 41,000 | $0 |
| 2023 | DAWN | 0 | $0 | 23,140 | $469,999 | 14,500 | $0 |
| 2022 | DAWN | 0 | $0 | 48,574 | $1,024,493 | 8,250 | $0 |
1. Spyre Therapeutics, Inc. (AGLE)
2. Day One Biopharmaceuticals, Inc. (DAWN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-12-01 | AGLE | Buy | 6,500 | 4.59 | 29,854 |
| 2017-02-15 | AGLE | Buy | 2,000 | 4.28 | 8,568 |
| 2016-08-15 | AGLE | Buy | 2,000 | 3.99 | 7,974 |
| 2017-12-05 | AGLE | Buy | 10,241 | 4.75 | 48,695 |
| 2017-08-15 | AGLE | Buy | 1,959 | 2.52 | 4,928 |
| 2017-12-04 | AGLE | Buy | 3,259 | 4.97 | 16,197 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-18 | DAWN | Sale | 4,106 | 6.77 | 27,785 |
| 2025-08-15 | DAWN | Option Ex | 16,875 | .00 | 0 |
| 2025-05-16 | DAWN | Sale | 4,282 | 6.26 | 26,796 |
| 2025-05-15 | DAWN | Option Ex | 16,875 | .00 | 0 |
| 2025-02-18 | DAWN | Sale | 4,370 | 11.96 | 52,278 |
| 2025-02-15 | DAWN | Option Ex | 16,875 | .00 | 0 |
| 2024-11-18 | DAWN | Sale | 2,602 | 13.21 | 34,372 |
| 2024-11-15 | DAWN | Option Ex | 10,250 | .00 | 0 |
| 2024-08-16 | DAWN | Sale | 2,633 | 14.00 | 36,859 |
| 2024-08-15 | DAWN | Option Ex | 10,250 | .00 | 0 |
| 2024-05-16 | DAWN | Sale | 2,675 | 16.08 | 43,011 |
| 2024-05-15 | DAWN | Option Ex | 10,250 | .00 | 0 |
| 2024-05-01 | DAWN | Sale | 52,183 | 17.89 | 933,397 |
| 2024-05-03 | DAWN | Sale | 8,078 | 17.85 | 144,216 |
| 2024-05-02 | DAWN | Sale | 200 | 17.90 | 3,579 |
| 2024-02-15 | DAWN | Option Ex | 10,250 | .00 | 0 |
| 2024-02-16 | DAWN | Sale | 2,666 | 15.25 | 40,651 |
| 2023-11-15 | DAWN | Option Ex | 3,625 | .00 | 0 |
| 2023-11-16 | DAWN | Sale | 956 | 11.69 | 11,175 |
| 2023-08-17 | DAWN | Sale | 922 | 13.86 | 12,778 |
| 2023-08-15 | DAWN | Option Ex | 3,625 | .00 | 0 |
| 2023-05-15 | DAWN | Option Ex | 3,625 | .00 | 0 |
| 2023-05-16 | DAWN | Sale | 955 | 13.12 | 12,531 |
| 2023-02-17 | DAWN | Sale | 9,377 | 20.03 | 187,793 |
| 2023-02-15 | DAWN | Option Ex | 3,625 | .00 | 0 |
| 2023-02-16 | DAWN | Sale | 930 | 19.57 | 18,202 |
| 2023-01-20 | DAWN | Sale | 10,000 | 22.75 | 227,520 |
| 2022-11-21 | DAWN | Sale | 10,000 | 21.06 | 210,640 |
| 2022-11-15 | DAWN | Option Ex | 1,375 | .00 | 0 |
| 2022-11-16 | DAWN | Sale | 430 | 21.46 | 9,227 |
| 2022-11-15 | DAWN | Option Ex | 1,375 | .00 | 0 |
| 2022-11-16 | DAWN | Sale | 430 | 21.46 | 9,227 |
| 2022-11-15 | DAWN | Option Ex | 1,375 | .00 | 0 |
| 2022-11-16 | DAWN | Sale | 430 | 21.46 | 9,227 |
| 2022-10-03 | DAWN | Sale | 10,000 | 20.05 | 200,470 |
| 2022-09-01 | DAWN | Sale | 10,000 | 23.48 | 234,790 |
| 2022-08-16 | DAWN | Sale | 1,089 | 24.31 | 26,473 |
| 2022-08-15 | DAWN | Option Ex | 4,125 | .00 | 0 |
| 2022-08-04 | DAWN | Sale | 10,000 | 20.05 | 200,539 |
| 2022-07-18 | DAWN | Sale | 2,500 | 20.00 | 50,000 |
| 2022-07-08 | DAWN | Sale | 1,416 | 20.00 | 28,320 |
| 2022-07-01 | DAWN | Sale | 1,479 | 20.00 | 29,580 |
| 2022-07-05 | DAWN | Sale | 800 | 20.00 | 16,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by York Charles N Ii (COO and CFO of Day One Biopharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.